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A b s t r a c t
Background: The influence of various factors on atrial fibrillation (AF) development in the population of tachycardia-bradycardia 
syndrome (TBS) patients remains unclear. There are no data on the impact of different right ventricular pacing percentage 
(RVp%) profiles. 
Aim: The purpose of the study was to evaluate the relationship between the AF burden (AFB) and various clinical, echocar-
diographic, and pacing parameters in TBS patients.
Methods: We performed a prospective, one-year registry of TBS patients with documented AF referred for dual-chamber 
pacemaker (DDD) implantation.
Results: The data of 65 patients were analysed. The median 12-month RVp% and AFB was 9.4% and 1.0%, respectively. 
During the follow-up 14% of patients had no AF (p = 0.003), and the withdrawal of AF symptoms was observed in 49% of 
patients (p < 0.0001). The AFB was related to the left atrium diameter (r = 0.31, p = 0.02), especially in the subjects with left 
ventricular ejection fraction < 60% (r = 0.44, p = 0.04). Based on the relative change of RVp%, three groups of various RVp% 
profile were established: stable, decreasing, and increasing RVp%. In the stable RVp% group (n = 21) there was a quadratic 
correlation between the 12-month RVp% and AFB (r = 0.71, p = 0.0003). In the stable RVp% > 20% subgroup there was 
a significant increase of AFB in comparison to the RVp% ≤ 20% subgroup (ΔAFB 1.8% vs. 0.0%, p = 0.03, respectively). In 
the increasing RVp% group (n = 28) the AFB increased whereas in the decreasing RVp% (n = 16) it remained stable (ΔAFB 
0.67% vs. 0.0%, p = 0.034, respectively). 
Conclusions: DDD implantation in TBS patients is related to a significant reduction in AF symptoms, and left atrial diameter 
correlates with cumulative AFB in the mid-term observation. Stable RVp% > 20% is associated with AF progression whereas 
lower stable RVp% may stabilise AF development. Increasing RVp% may be associated with the AFB increase in comparison 
to the decreasing RVp% subgroup in which AFB remains stable. 
Key words: tachycardia-bradycardia syndrome, right ventricular pacing percentage, atrial fibrillation burden, dual chamber 
pacemaker, left ventricular ejection fraction
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INTRODUCTION
The influence of multiple clinical, echocardiographic and 
pacing factors, including the right ventricular pacing per-
centage (RVp%), on the development of atrial fibrillation 
(AF) and heart failure progression has been examined for 
decades. However, the population of patients suffering from 
tachycardia-bradycardia syndrome (TBS), i.e. a specific form 
of sinus node disease coexisting with supraventricular tachy-
cardias, is often neglected, underscored, or not distinguished 
in those studies, which were predominantly performed in the 
times of different pacing paradigms [1, 2]. 
Moreover, the methods of AF progression assessment 
used in previous studies, especially by counting the number of 
symptomatic AF episodes, seems questionable in light of cur-
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rent medical knowledge because it has been proven that they 
do not reflect properly the real AF advancement compared 
with the continuous methods of rhythm assessment [3–5]. 
As a result, it still remains unclear what factors are associ-
ated with AF occurrence in patients with TBS and implanted 
DDD pacemakers characterised by a low percentage of right 
ventricular paced beats. 
The aim of this study was to examine prospectively the 
influence of dual-chamber pacemaker implantation on the 
occurrence of AF, the correlations between the AF progression 
measured continuously as an AF burden (AFB) and different 
echocardiographic and pacing parameters with the special 
inclusion of RVp% in a group of patients with TBS.
METHODS
The study was conducted according to the declaration of 
Helsinki, and its protocol was approved by a local institutional 
Ethics Committee. Before entering the study, all patients pro-
vided informed consent.
We performed a prospective registry of 82 consecutive 
patients with symptomatic TBS, who had been qualified for 
dual chamber pacemaker implantation in our Department. 
We included patients if they were 35–80 years old, could 
provide written informed consent, and had at least two 
symptomatic paroxysms of AF in the 12-month period prior 
to the pacemaker implantation. At least one of the paroxysms 
had to be documented in medical records. Patients were 
not included if their clinical status was unstable or they had 
concomitant diseases that could adversely affect their prog-
nosis or the progression of the arrhythmia. The inclusion and 
exclusion criteria are listed in Table 1.
Qualification for device implantation
Qualifications for device implantation were performed col-
lectively by a team of experienced electrophysiologists based 
on the previous medical history and documentation of each 
patient, according to current guidelines on pacemaker device 
implantation. The preferred site of right ventricular electrode 
was mid-low interventricular septum or apical if the septal 
position was difficult to achieve. 
Control visits and follow-up
The patients’ follow-up lasted one year and consisted of four 
visits performed a day, eight weeks, six months, and 12 months 
after the implantation. On each visit, a regular control of the 
device parameters was performed and the data concerning 
RVp%, percentage of atrial paced beats (Ap%), and AFB were 
taken. The mentioned parameters were expressed as cumula-
tive values, i.e. total RVp%, Ap%, and AFB beginning from the 
pacemaker implantation to the follow-up day. 
According to current guidelines, the devices were pro-
grammed in such a way so as to minimise right ventricular 
pacing by atrio-ventricular (AV) prolongation, avoidance of 
rate response function, and introduction of the manufactur-
er’s specific algorithms to minimise RVp% — if relevant. The 
basic mode of programming was a DDD mode with a base 
rate of 50 bpm and AV delay of 250 ms. The rate response 
function (DDDR mode) was omitted. On each visit the patient 
was questioned about the number of symptomatic paroxysms 
of AF and current pharmacotherapy. Moreover, each partici-
pant underwent echocardiographic examination performed 
on the day following the device implantation and on the 
12-month visit. During echocardiographic examination an 
assessment of the left atrium diameter (LAd), left ventricular 
end-systolic, and end-diastolic diameter (LVESd and LVEDd) 
measured from a parasternal long-axis view as well as the 
left ventricular ejection fraction (LVEF) was performed using 
the Simpson method. 
Atrial fibrillation burden
Atrial fibrillation burden was defined as a percentage of 
follow-up time spent in atrial tachyarrhythmia (atrial fibril-
lation/atrial flutter/atrial tachycardia) with a P-wave rate 
of 200 bpm or faster, which gave an adequate pacemaker 
response, i.e. resulting in mode-switching of a device to DDI 
stimulation pattern. If the default settings of AF diagnosis in 
the implanted pacemakers had been different to the one as-
sumed in our study, the devices were reprogrammed so as to 
meet the study AF recognition criteria. Similarly to the basic 
DDD mode, we omitted rate response function during the 
“mode switch” DDI mode. 
Due to the possibility of overestimation of AFB by im-
proper mode switching of the devices, we carefully revised 
Table 1. The study inclusion and exclusion criteria
Inclusion criteria
Tachycardia-bradycardia syndrome
Indication for dual chamber pacemaker
Age: 35–80 years
At least two symptomatic atrial fibrillation paroxysms during the 
12 months preceding inclusion (with at least one documented)
Written informed consent
Exclusion criteria
Less than six months since myocardial infarction/acute coronary 
syndrome
Heart failure — New York Heart Association III or IV
Valvular heart disease after surgical treatment
Thyroid dysfunction
Chronic obstructive pulmonary disease
Other inflammatory diseases
Cancer
Chronic use of steroids
Less than three months since major surgery
Pulmonary vein isolation in anamnesis
Simultaneous participation in another clinical trial
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all of the intracardiac electrocardiograms that were available 
during the follow-up and refused “false” recordings. 
During follow-up we analysed a change in AFB (delta 
AFB, DAFB) based on the results of cumulative AFB on the 
eight-week and 12-month visits. We recognised AFB as in-
creasing or decreasing if the absolute change in AFB exceeded 
1% or –1%, respectively. AFB was termed stable if the absolute 
difference between the values obtained on the eight-week 
and 12-month visit was less than 1%. 
Statistical analysis
Descriptive statistics for qualitative variables were reported as 
frequencies and percentages and compared using the c2 test 
or Fisher’s exact test. 
Quantitative data were expressed as mean ± standard 
deviation if normally distributed or median and interquar-
tile range if not normally distributed. Continuous variables 
were tested for normal distribution with the use of the 
Kolmogorow-Smirnow test. Means (median) between the two 
categories were compared by unpaired Student’s t-test or the 
Mann-Whitney U test, as appropriate. Differences between 
the three groups were assessed by a one-way analysis of vari-
ance (with the Tukey’s multiple range post-hoc tests) or the 
Kruskall-Wallis analysis of variance (ANOVA). The correlation 
analyses were done by the Pearson or the Spearman’s test. 
Univariate regression analysis was performed to assess squared 
relationships between variables.
All analyses were performed using SAS software version 9.2 
(SAS, Cary, NC, USA). Two-sided p values < 0.05 were 
considered to be statistically significant.
RESULTS
Study population
The analysed registry consisted of 82 consecutive patients 
(65% females) with TBS, who met the inclusion and exclusion 
criteria and had been qualified for dual-chamber pacemaker 
implantation in our Department from February 2010 to Janu-
ary 2013. The mean patients’ age was 72 ± 6.8 years. The 
mean follow-up time was 368 ± 63 days. The patients re-
ceived pacemakers from various manufacturers, including: 
Victory XL (St Jude Medical, Sylmar, CA, USA), Talos DR 
(Biotronik, Berlin, Germany), and E60A and G70 (Vitatron, 
Maastricht, Netherlands). The choice for the pacemaker was 
restricted to current availability of the products and was made 
at the implanting physician’s discretion. The analysed group 
was characterised by a low median RVp% of 9.4% (Q1–Q3: 
2.2–38.5) and low AFB (median: 1.0% [0.0–5.1]). The cumula-
tive Ap% was 36.8 ± 27.6%.
The final analysis was performed on a group of 65 pa-
tients, having excluded those with incomplete data neces-
sary for the analysis (seven patients), patients with serious 
AV conduction abnormalities resulting in cumulative RVp% 
exceeding 90% (seven patients), and patients with persistent 
AF that lasted throughout the whole follow-up period (three 
patients). The baseline characteristics of the studied popula-
tion are shown in Table 2. 
The incidence of AF and its symptoms  
during the follow-up period
During the 12-month follow-up period nine (13.8%) patients 
remained free from AF paroxysms, which was defined as no 
AFB at all (i.e. no time spent in the auto mode switch). There 
was a significant reduction of the AF incidence in compari-
son to the time before the pacemaker implantation (86.2% 
vs. 100%; p = 0.003). The reduction of the symptomatic AF 
paroxysm was greater, i.e. 30 (49.2%) patients had no symp-
toms at all during the follow-up (p < 0.0001).
Echocardiographic indices and AFB
In the entire group there was a linear correlation between the 
AFB and LAd both measured at a 12-month visit (r = 0.31, 
p = 0.02; Fig. 1). Moreover, in patients who had AF parox-
ysms during the whole follow-up period the LAd increased 
significantly more often than in those who did not have any 
paroxysms of AF at the beginning of observation (AFB at the 
eight-week follow-up was 0) and remained practically free 
from AF during the whole follow-up (AFB at the 12-month 
follow-up < 1%), i.e. 35% vs. 8.7%, (p = 0.03). In patients 
with reduced LVEF (that is LVEF < 60%) the correlation be-
came stronger (r = 0.44, p = 0.04; Fig. 1). 
These correlations between the AFB and LAd were not 
related to the RVp%. Both in the whole group and in patients 
with reduced LVEF we found no correlations between the RVp% 
and the LAd measured at the 12-month follow up (r = 0.01, 
p = 0.92 and r = –0.04, p = 0.84, respectively). Similarly, there 
were no correlations of the AFB or LAd with the left ventricular 
diameter (i.e.: LVESd and LVEDd) and LVEF.
Right ventricular pacing, its profiles, and AFB
Overall. In the entire group we found no linear correlations 
of cumulative AFB with either RVp% or Ap% (Fig. 2). How-
ever, while examining the subgroups of patients according to 
RVp% change in time, the influence of RVp% and its profile 
became significant.
Different profiles of the right ventricular  
pacing percentage
Based on a relative difference in RVp% between the 
eight-week visit and 12-month visit, the examined population 
was divided into three categories with different RVp% profiles:
 — if the RVp% increased more than 25% of the value meas-
ured at the eight-week visit, the patient was assigned to 
the group of increasing RVp% (I-RVp%);
 — the group of decreasing RVp% (D-RVp%) consisted of 
patients in whom RVp% decreased more than 25% from 
the eight-week to 12-month follow-up visit; 
www.kardiologiapolska.pl
Parameters affecting atrial fibrillation burden in tachycardia-bradycardia patients
341
 — if a relative change in RVp% during follow-up did not 
exceed 25% the RVp% profile was recognised as stable 
(S-RVp% group).
Based on the value of RVp% on the 12-month visit, the 
S-RVp% was divided into two subgroups: 
1 the patients with stable high RVp% if RVp% exceeded 
20% (S-RVp% > 20%);
2 the patients with stable low RVp% if RVp% was ≤ 20% 
(S-RVp% ≤ 20%).
There were no differences in the baseline charac-
teristics between the analysed groups except for the his-
tory of previous myocardial infarction, which was most 
prevalent in the stable RVp% group. However, there were 
statistically significant differences in the baseline (i.e. the 
eight-week) RVp% between the increasing RVp% and the 
decreasing RVp% groups (14.7% vs. 1.9%, p = 0.007). 
The groups did not differ as to the pharmacological 
treatment, including the use of the typical antiarrhyth-
mic drugs, beta-blockers, or anticoagulants (Table 2). 
We did not observe any differences in the prevalence of in-
terventricular conduction disturbances between the analysed 
groups, which generally was a rare finding.
Table 2. Baseline characteristics of the studied population and its right ventricular pacing percentage profile subgroups









Age [years] 71.5 ± 6.8 72.5 ± 5.8 69.8 ± 6.1 72.4 ± 7.8 0.4
Females 44/65 (67.7%) 9/16 (56.2%) 17/21 (80.9%) 18/28 (64.3%) 0.3
BMI [kg/m2] 28.4 ± 4.0 26.8±2.7 27.9 ± 4.4 30.1 ± 4.0 0.2
CHA2DS2-VASc score 3.21 ± 1.14 3.31 ± 1.14 3.32 ± 1.44 3.86 ± 1.35 0.3
Comorbidities:
CAD 19 (29.3%) 3 (18.7%) 10 (47.6%) 6 (21.4%) 0.08
Myocardial infarction 9 (13.9%) 0 (0%) 7 (33.3%) 2 (7.1%) 0.007*
Previous PTCA 7 (11.0%) 0 (0%) 4 (19.1%) 3 (10.7%) 0.2
Previous CABG 1 (1.5%) 0 (0%) 1 (4.8%) 0 (0%) 0.6
Arterial hypertension 57 (87.7%) 13 (81.2%) 20 (95.2%) 24 (85.7%) 0.3
Diabetes mellitus 12 (18.5%) 2 (12.5%) 4 (19.0%) 6 (21.4%) 0.9
Smoking 11/41 (26.8%) 2/13 (15.4%) 5/13 (38.5%) 4/14 (26.7%) 0.6
Hyperlipidaemia 38/64 (59.4%) 7 (46.7%) 15 (71.4%) 16 (57.1%) 0.3
Previous stroke 3 (4.6%) 1 (6.2%) 0 (0%) 2 (7.1%) 0.6
Arteriosclerosis obliterans 3 (4.8%) 0 (0%) 2 (9.5%) 1 (3.8%) 0.6
IVCD 8 (12.5%) 3 (18.8%) 3 (14.3%) 2 (7.4%) 0.5
Pharmacological treatment:
Beta-blockers 46/56 (82.1%) 8/12 (66.7%) 16/20 (80%) 22/24 (91.7%) 0.2
Calcium blockers 21/57 (36.8%) 5/12 (41.7%) 8/20 (40.0%) 8/25 (32%) 0.8
Digitalis 1/57 (1.7%) 0/12 (0%) 1/20 (5%) 0/25 (0%) 0.6
Antiarrhythmics 25/57 (43.9%) 7/12 (58.3%) 8/20 (40%) 10/25 (40%) 0.5
Statins 31/57 (54.4%) 4/12 (33.3%) 13/20 (65%) 14/25 (56%) 0.2
Fibrates 4/56 (7.1%) 1/12 (8.3%) 2/20 (10%) 1/24 (4.2%) 0.8
Diuretics 26/57 (45.6%) 5/12 (41.7%) 9/20 (45%) 12/25 (48%) 0.9
Aldosterone antagonists 9/57 (15.8%) 3/12 (25.0%) 3/20 (15%) 3/25 (12%) 0.6
ACE-I 29/57 (50.9%) 7/12 (21.1%) 11/20 (55%) 11/25 (44%) 0.6
Anticoagulants 36/57 (63.2%) 7/12 (58.3%) 14/20 (70%) 15/25 (58.8%) 0.9
Acetylsalicylic acid 17/57 (29.8%) 1/12 (8.3%) 7/20 (35%) 9/25 (36.0%) 0.2
Clopidogrel 3/57 (5.3%) 0/12 (0.0%) 1/20 (5%) 2/25 (8.0%) 1.0
Anti-diabetics 8/57 (14.0%) 1/12 (8.3%) 2/20 (10%) 5/25 (20.0%) 0.7
*A p value of < 0.05 is considered statistically significant. Data are presented as mean ± standard deviation or median (95% confidence interval) 
or number/number of observations (percentage) — as appropriate; ACE-I — angiotensin converting enzyme inhibitors; BMI — body mass index; 
CABG — coronary artery by-pass grafting; CAD — coronary artery disease; D-RVp% — decreasing right ventricular pacing percentage; I-RVp% — 
increasing right ventricular pacing percentage; IVCD — interventricular conduction delay (defined as a native QRS complex duration > 120 ms); 
PTCA — percutaneous transluminal coronary angioplasty; S-RVp% — stable right ventricular pacing percentage
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Figure 1. Plots showing correlations between the left atrium diameter (LA) and the atrial fibrillation burden (AFB; top) and  
between the right ventricular paced beats percentage (RVp%) and the ejection fraction (EF; bottom) measured at12 months.  
The left side shows correlations in the whole group and the right side — in patients with EF less than 60%; p — probability
Figure 2. Plots showing lack of significant correlations between cumulative 12-month atrial fibrillation burden (AFB) and cumu-
lative 12-month atrial paced beats percentage (Ap%, A) and cumulative 12-month right ventricular paced beats percentage 
(RVp%; B); N — number of observations; p — probability; r — “rho” correlation coefficient
0 020 2040 40
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The groups with various RVp% profiles did not differ 
between each other on other echocardiographic measure-
ments except for a statistically significant difference in the 
LVEF at 12 months. Surprisingly, during the follow-up the LVEF 
decreased slightly but statistically significantly in the D-RVp% 
(ΔEF = –2 ± 4, p = 0.03), whereas in the remaining I-RVp% 
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and S-RVp% it was stable, which led to that difference be-
tween the LVEF at the 12-month time point.
The increasing versus the decreasing right  
ventricular pacing groups (I-RVp% vs. D-RVp%) 
In the D-RVp% group (n = 16) there was a tendency for 
stabilisation of AFB during the follow-up period compared 
with patients in whom RVp% increased (n = 28). In the 
D-RVp% group the AFB increased in as few as two (12.5%) 
patients and remained stable or decreased in the remaining 
87.5%, whereas in the I-RVp% the AFB increased in 11 (39%) 
subjects and decreased in a single patient (7%) (Fig. 3). These 
differences were not significant. However, the ΔAFB between 
the D-RVp% and I-RVp% groups differed significantly (0.0% 
vs. 0.67%, p < 0.04, respectively).
The stable right ventricular  
pacing group (S-RVp%)
In the S-RVp% group (n = 21) we found a strong correlation 
between the cumulative RVp% and AFB, both measured in 
the 12-month observation (r = 0.71, p = 0.0003). The cor-
relation was quadratic. The plot resembled a J curve with the 
turning point close to RVp% = 20%: when RVp% increased 
and its value exceeded 20% the AFB increased as well; when 
the RVp% was less than 20% the AFB increased with the 
decrease of RVp% (Fig. 4).
In the subgroup with stable-low RVp% (S-RVp% ≤ 20%), 
AFB tended to remain unaltered during the follow-up period 
in the majority of patients (85%) whereas in the stable-high 
subgroup (S-RVp% > 20%) it was stable in only 37.5% and in 
the remaining 62.5% AFB increased (p = 0.01; Fig. 5). The 
overall change in AFB during the follow-up (ΔAFB) differed 
significantly between the stable-low RVp% and the stable-high 
RVp% groups (ΔAFB 0.0 vs. +1.8%, p < 0.03, respectively). 
Right ventricular pacing and the LVEF
Cumulative 12-month RVp% correlated negatively with LVEF 
measured at the last follow-up visit (r = –0.26, p = 0.04) and 
in patients with reduced LVEF (i.e. LVEF < 60%) the correla-
tion became stronger (r = –0.53, p = 0.01 for RVp%; Fig. 1). 
DISCUSSION
The incidence of AF and its symptoms  
during the follow-up period
The withdrawal of symptoms in a significant number of pa-
tients is an expected finding. Implantation of a pacemaker 
enables us to uptitrate chrono- and dromotropic drugs to slow 
down the rhythm of the ventricles during the AF paroxysm 
and diminishes the symptoms reported by the patients. Sur-
prisingly there have been no papers to support this concept 
and the previously published data is contradictory [6]. The 
withdrawal of AF, defined as no AFB at all, observed in our 
study is a novel finding. It may also be related with higher 
drug doses but it needs further analysis, while the influences 
between the pharmacological treatment, cardiac pacing, and 
development of AF is a very complex issue. It encompasses 
many mechanisms that may influence each other, such us 



















 Increasing  Stable or AFB [95% CI] Delta AFB
 AFB decreasing
  AFB
D-RVp% 2 (12.5%) 14 (87.5%) 0.38 [0.01–4.44] 0.0 [–1.05; –0.02]
I-RVp% 11 (39%) 17 (61%) 1.0 [0.12–5.50] +0.67 [–0.11; 2.17]
p                          0.09  0.5 0.036*
Figure 3. Bar chart and table showing differences in atrial 
fibrillation burden (AFB) change during 12-month follow-up in 
decreasing right ventricular paced beats percentage (D-RVp%) 
and increasing right ventricular paced beats percentage (I-RVp%) 
subgroups; *A p value < 0.05 is considered statistically  
significant; delta AFB — absolute AFB change between the 












Figure 4. Correlation of AFB with cumulative RVp% in 
the group with stable RVp%. Square regression equation: 
AFB = 0.005*(RVp%)2 – 0.223*RVp%_12m12 + 1.869; 
R2 = 0.596. Correlation of AFB with square RVP%: r = 0.71; 
p = 0.0003; AFB — cumulative 12-month atrial fibrillation 
burden; RVp% — cumulative 12-month right ventricular 
pacing percentage
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ence of changes in the drugs’ dosage, let alone the effect of 
ventricular pacing, which should be further discussed. The 
explanation of this observation is beyond the scope of the 
current study. 
Echocardiographic indices and AFB
A correlation between the LAd and AFB observed in the 
present study is in line with previous reports that found that 
the LA enlargement and its extent are related to the advance-
ment of AF [7, 8]. However, to the best of our knowledge, our 
study proves for the first time the direct correlation between 
the LAd and AFB in TBS patients. 
It has been hypothesised that LA enlargement could link 
the detrimental cumulative effect of RVp% with AF progres-
sion. As a result of pathological ventricular contraction due 
to excessive cumulative RVp% the LA would enlarge, and 
this could lead to AF progression [3, 9]. Our study does not 
support this view, where we have not found any significant 
correlation between LA and RVp%. The same holds true for 
such associations in the whole study population and in any of 
the RVp% profile subgroups. These findings suggest that the 
detrimental effect of RVp% on AFB may be related to atrial 
pressure overload and contractility impairment rather than 
atrial enlargement itself [8, 10]. Atrial enlargement would 
be a result rather than a cause of AF progression in this case, 
which agrees also with available evidence [11]. 
Right ventricular pacing and AFB
While the harmful effect of high mid- and long-term RVp% 
seems unquestionable, there was a lack of evidence showing 
whether the amount of RVp% still affects the progression of AF 
in patients receiving devices programmed to minimise RVp%. 
Additionally, the progression of AF was measured mainly by 
assessing the progression of paroxysmal AF to its persistent 
form in previous studies, but the data showing a correlation 
between the RVp% and AFB were inconsistent [3, 12]. 
Continuous measurement of AFB seems to reflect bet-
ter the AF advancement, poorly correlates with the risk of 
persistent AF [3–5], and seems to be more clinically relevant 
in terms of the risk of stroke in patients with asymptomatic 
paroxysmal AF. To the best of our knowledge, the presented 
study proves for the first time that the detrimental effect of RVp 
on AFB is also noticeable in the population of TBS patients 
with low cumulative RVp%, where the given amount of stable 
RVp% has a strong influence on AFB. However, stable RVp% 
lower than 20% does not seem to play any important role in 
AF progression.
The presented paper examines for the first time the influ-
ence of different RVp% profiles on AFB. Our study suggests 
that not only the cumulative RVp% itself influences the AF 
burden but also whether RVp% increases, decreases, or is 
stable over time. 
Although we have not shown that the influence of the 
RVp% profile on AFB is independent of the cumulative 
RVp% itself, there exists indirect evidence that supports this 
thesis. Such a hypothesis neatly explains the fact that there 
is a lack of correlation between cumulative RVp% and AFB 
in the whole examined group and, simultaneously, strong 
correlation between those factors in the stable RVp% group. 
On the other hand, the lack of strong differences between 
the I-RVp% and D-RVp% groups in regard to AFB may be 
explained by the fact that the patients in the D-RVp% group 
had significantly higher initial RVp%, but at 12 months the 
cumulative RVp% equalised in those groups. 
Finding a mechanism that would explain the link be-
tween the RVp% profile and AFB progression is challenging. 
Indeed, the progression of AF in patients with pacemakers 
is a more complex issue than only a simple correlation 
between the detrimental effect of cumulative RVp% on the 
AF incidence. It has been shown that in those patients the 
incidence of AF may have different patterns beginning from 
non-progressive, chronic progressive or relapsing-remitting 
paroxysmal AF [13], and the AF pattern has not been related 
to any of the clinical features examined. Because there are 
some links between the incidence of AV block and sinus node 
disease like the elevated risk of AV block in patients with sinus 
node disease [14, 15] or potentially the same genetic fac-
tors [16] and there exist such correlations between the sinus 
node disease and the AF [17, 18], it is possible that the RVp% 
changes in the presented study may reflect the advancement 
Figure 5. Bar chart and table showing differences in atrial 
fibrillation burden (AFB) change during 12-month follow-up 
in the stable low RVp% (S-RVp% ≤ 20%) and the stable high 
RVp% (S-RVp% > 20%) subgroups; *A p value of < 0.05 is 
considered statistically significant; delta AFB — absolute AFB 
change between the eight-week and the 12-month time point; 
p — probability; S-RVp% — stable right ventricular paced 
beats percentage group
S-RVP% Decreasing  Increasing Stable AFB AFB [95% CI] Delta AFB
 AFB AFB
 20% 1 (7.5%) 1 (7.5%) 11 (85%) 0.12 [0.0–1.00] 0.0 [–0.18–0.00]
> 20% 0 (0%) 5 (62.5%) 3 (37.5%) 2.71 [0.5–7.35] +1.8 [0.0–3.56]
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of the disease affecting simultaneously both nodes and atria. 
Such a hypothesis may explain the correlations between 
the AV prolongation and AF progression observed in some 
large studies [12, 19]. Moreover, it neatly explains why more 
sophisticated algorithms of avoiding right ventricular pacing 
fail to show the clear benefit of further RVp% reduction in 
terms of AF development [15, 20, 21]. The benefit of right 
ventricular pacing avoidance would be compensated in 
those cases by the detrimental effect of a too long AV delay 
and greater advancement of the degenerative disease con-
cerning the atria and both nodes in which AV prolongation 
would be a sign rather than a cause. The results of our study 
showing a negative correlation between the RVp% and AF 
in the subpopulation of very small stable RVp% may also be 
explained by the mentioned thesis. 
Right ventricular pacing and the LVEF
Our finding of a linear correlation between the RVp% and 
LVEF supports the evidence suggesting that there is some 
detrimental effect of non-physiological RV pacing on the ven-
tricular function [1, 3, 22], which becomes more apparent in 
subjects with already reduced LVEF. However, until now there 
have not been sufficient data concerning this correlation in the 
subgroup of patients characterised by low RVp%. The recent 
retrospective evidence questions the clinical relevance of such 
an influence, especially in subjects with preserved LVEF [23], 
but the assessment of cumulative RVp% in the cited paper 
could have been substantially different to our study. 
It is difficult to explain why the only subpopulation in 
which the LVEF reduced was the D-RVp% group. Because of 
the fact that in this group the cumulative RVp% was signifi-
cantly the highest at the initial eight-week observation and 
then it became similar to the one observed in the I-RVp% 
group (7.8 [2.8–15.9] vs. 9.6 [3.1–35.4], p = 0.3), one may 
speculate that, unlike AFB progression, LVEF% seem to be 
mainly affected by cumulative RVp% itself but not the RVp% 
profile.
Limitations of the study
One of the limitations of the study is a fairly small group of 
analysed patients, which hampers the statistical power of 
the results and hinders more precise, multifactorial analysis.
Additionally, the study lacks the ability to adequately 
assess the influence of drug usage on the results. One of the 
reasons is the already mentioned small number of analysed 
subgroups. Another is the fact that the baseline treatment 
was assessed on the day of discharge from hospital after the 
pacemaker implantation, so we have no reliable data con-
cerning the intensification of the treatment immediately after 
the implantation. However, it must be stressed that during 
the follow-up we observed no substantial changes in the us-
age of antiarrhythmic drugs (mainly propafenone and rarely 
amiodarone). Moreover, the hypothetical protective effect 
of beta-blockers could have only hindered the influence of 
the RVp% on the AFB development, while the intensification 
of treatment with beta-blockers would have only lead to an 
increase of the RVp%.
The definition of the AF paroxysms used in our work 
are not the same as the current definition of atrial high-rate 
episodes (AHREs) [24], but at the time of the development 
of the protocol for our study the evidence about the clinical 
relevance and clear definitions of AHRE were not yet avail-
able. As we took into consideration the episodes that lasted 
less than 30 s our mode of assessing AFB was more sensitive. 
However, we revised all of the accessible intracardiac elec-
trocardiograms and rejected the false positive ones. 
Another limitation may be the possible influence of the 
right ventricular electrode localisation (i.e. the RV apex or RV 
middle/distal septum) on the study data. However, a recent 
study of Ng et al. [25] suggests that there are no significant 
differences in the long-term haemodynamic effect during 
pacing in those two locations.
During the study we could not discriminate the fusion 
and the pseudofusion beats from the true paced ones, so the 
real RVp% might have been overestimated. However, except 
for the continuous long-term electrocardiogram monitoring 
methods, which are expensive and affect the quality of life of 
the patients, there is no good method to overcome this prob-
lem, and it was not evaluated in other studies on this subject.
Finally, the analysis of the influence of different RVp% 
profiles on other parameters was performed post hoc. How-
ever, it has to be underlined that the data from the registry 
was collected prospectively. 
CONCLUSIONS
The DDD implantation in TBS patients is related to significant 
reduction of AF symptoms. The LAd in these patients corre-
lates with cumulative AFB in the mid-term observation. AFB is 
may not only be related to the RVp% value but its change in 
time. Increasing RVp% may be connected to the AFB increase 
in comparison to the decreasing RVp% subgroup in which AFB 
remains stable. The value of stable RVp% correlates strongly 
with AFB and the correlation is quadratic. Stable RVp% > 20% 
is associated with AF progression whereas lower stable RVp% 
may stabilise AF development.
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